Logo image of CLSD

CLEARSIDE BIOMEDICAL INC (CLSD) Stock Fundamental Analysis

USA - NASDAQ:CLSD - US1850631045 - Common Stock

3.98 USD
-0.38 (-8.72%)
Last: 10/10/2025, 9:18:22 PM
Fundamental Rating

2

Taking everything into account, CLSD scores 2 out of 10 in our fundamental rating. CLSD was compared to 196 industry peers in the Pharmaceuticals industry. CLSD has a bad profitability rating. Also its financial health evaluation is rather negative. CLSD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLSD had negative earnings in the past year.
CLSD had a negative operating cash flow in the past year.
CLSD had negative earnings in 4 of the past 5 years.
In the past 5 years CLSD always reported negative operating cash flow.
CLSD Yearly Net Income VS EBIT VS OCF VS FCFCLSD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

CLSD's Return On Assets of -180.75% is on the low side compared to the rest of the industry. CLSD is outperformed by 87.76% of its industry peers.
Industry RankSector Rank
ROA -180.75%
ROE N/A
ROIC N/A
ROA(3y)-98.81%
ROA(5y)-77.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLSD Yearly ROA, ROE, ROICCLSD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 90.47%, CLSD belongs to the top of the industry, outperforming 93.88% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for CLSD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLSD Yearly Profit, Operating, Gross MarginsCLSD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K -250K

More info and screens

3

2. Health

2.1 Basic Checks

CLSD does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLSD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLSD has been increased compared to 5 years ago.
CLSD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLSD Yearly Shares OutstandingCLSD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLSD Yearly Total Debt VS Total AssetsCLSD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CLSD has an Altman-Z score of -37.16. This is a bad value and indicates that CLSD is not financially healthy and even has some risk of bankruptcy.
CLSD has a Altman-Z score of -37.16. This is amonst the worse of the industry: CLSD underperforms 88.27% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -37.16
ROIC/WACCN/A
WACC8.69%
CLSD Yearly LT Debt VS Equity VS FCFCLSD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

CLSD has a Current Ratio of 3.87. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.
CLSD has a Current ratio of 3.87. This is in the better half of the industry: CLSD outperforms 62.76% of its industry peers.
A Quick Ratio of 3.87 indicates that CLSD has no problem at all paying its short term obligations.
CLSD has a Quick ratio of 3.87. This is in the better half of the industry: CLSD outperforms 63.78% of its industry peers.
Industry RankSector Rank
Current Ratio 3.87
Quick Ratio 3.87
CLSD Yearly Current Assets VS Current LiabilitesCLSD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CLSD have decreased strongly by -472.92% in the last year.
CLSD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -44.64%.
Measured over the past years, CLSD shows a decrease in Revenue. The Revenue has been decreasing by -5.17% on average per year.
EPS 1Y (TTM)-472.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
Revenue 1Y (TTM)-44.64%
Revenue growth 3Y-61.68%
Revenue growth 5Y-5.17%
Sales Q2Q%446.67%

3.2 Future

Based on estimates for the next years, CLSD will show a very strong growth in Earnings Per Share. The EPS will grow by 73.23% on average per year.
CLSD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 114.05% yearly.
EPS Next Y-631%
EPS Next 2Y-74.93%
EPS Next 3Y-79.46%
EPS Next 5Y73.23%
Revenue Next Year107.81%
Revenue Next 2Y155.35%
Revenue Next 3Y112.64%
Revenue Next 5Y114.05%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLSD Yearly Revenue VS EstimatesCLSD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
CLSD Yearly EPS VS EstimatesCLSD Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLSD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLSD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLSD Price Earnings VS Forward Price EarningsCLSD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLSD Per share dataCLSD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A cheap valuation may be justified as CLSD's earnings are expected to decrease with -79.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-74.93%
EPS Next 3Y-79.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLSD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARSIDE BIOMEDICAL INC

NASDAQ:CLSD (10/10/2025, 9:18:22 PM)

3.98

-0.38 (-8.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners14.91%
Inst Owner Change-1.72%
Ins Owners7.32%
Ins Owner Change0%
Market Cap20.82M
Analysts73.85
Price Target64.26 (1514.57%)
Short Float %N/A
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.21%
Min EPS beat(2)0.67%
Max EPS beat(2)41.76%
EPS beat(4)3
Avg EPS beat(4)15.66%
Min EPS beat(4)-0.93%
Max EPS beat(4)41.76%
EPS beat(8)6
Avg EPS beat(8)12.33%
EPS beat(12)6
Avg EPS beat(12)-17.47%
EPS beat(16)9
Avg EPS beat(16)-10.12%
Revenue beat(2)2
Avg Revenue beat(2)713.73%
Min Revenue beat(2)183.74%
Max Revenue beat(2)1243.71%
Revenue beat(4)4
Avg Revenue beat(4)556.39%
Min Revenue beat(4)69.81%
Max Revenue beat(4)1243.71%
Revenue beat(8)6
Avg Revenue beat(8)324.98%
Revenue beat(12)8
Avg Revenue beat(12)278.94%
Revenue beat(16)10
Avg Revenue beat(16)207.31%
PT rev (1m)1400%
PT rev (3m)1060.52%
EPS NQ rev (1m)-1400%
EPS NQ rev (3m)-465.37%
EPS NY rev (1m)-1400%
EPS NY rev (3m)-673.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-53.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)23.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.75
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0.8
BVpS-9.32
TBVpS-9.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -180.75%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.47%
FCFM N/A
ROA(3y)-98.81%
ROA(5y)-77.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.66%
Cap/Sales 12.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.87
Quick Ratio 3.87
Altman-Z -37.16
F-Score3
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)1083.74%
Cap/Depr(5y)656.91%
Cap/Sales(3y)33.04%
Cap/Sales(5y)19.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-472.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
EPS Next Y-631%
EPS Next 2Y-74.93%
EPS Next 3Y-79.46%
EPS Next 5Y73.23%
Revenue 1Y (TTM)-44.64%
Revenue growth 3Y-61.68%
Revenue growth 5Y-5.17%
Sales Q2Q%446.67%
Revenue Next Year107.81%
Revenue Next 2Y155.35%
Revenue Next 3Y112.64%
Revenue Next 5Y114.05%
EBIT growth 1Y15.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.3%
EBIT Next 3Y17.64%
EBIT Next 5YN/A
FCF growth 1Y13.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.81%
OCF growth 3YN/A
OCF growth 5YN/A